Disc Medicine (IRON) said Monday that it presented data supporting the advancement of its three investigational drugs.
The company said phase 2 studies showed that its drug candidate bitopertin reduces protoporphyrin IX levels and improves symptoms in adults and adolescents with erythropoietic protoporphyria, a genetic condition that can lead to liver disease.
Updates from pre-clinical studies showed a combination of ruxolitinib with DISC-0974's mouse analog showed potential as a treatment for anemia in myelofibrosis and inflammatory bowel disease, according to the company.
The company also said that DISC-3405 reduced serum iron levels and was well-tolerated in healthy volunteers, suggesting potential for treating polycythemia vera and sickle cell disease.
Shares of the company were down 1.5% in recent trading.
Price: 63.88, Change: -0.94, Percent Change: -1.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。